On Oct 24, major Wall Street analysts update their ratings for $Quest Diagnostics (DGX.US)$, with price targets ranging from $165 to $185.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $165 to $185.
Barclays analyst Stephanie Davis maintains with a hold rating, and adjusts the target price from $154 to $168.
Evercore analyst Elizabeth Anderson CFA maintains with a hold rating, and maintains the target price at $165.
Baird analyst Eric Coldwell upgrades to a buy rating, and adjusts the target price from $157 to $182.
Truist Financial analyst David S Macdonald maintains with a hold rating, and adjusts the target price from $165 to $172.
Furthermore, according to the comprehensive report, the opinions of $Quest Diagnostics (DGX.US)$'s main analysts recently are as follows:
The revised guidance for Quest Diagnostics is primarily attributed to the integration of LifeLabs, accompanied by sustained high utilization trends. The defensive characteristics of Quest, especially around an election cycle, and the more secure estimates for future years are viewed positively.
Quest Diagnostics delivered a strong third-quarter performance, characterized by exceeding expectations and maintaining earnings guidance even amid hurricane challenges. Additionally, the company provided an encouraging preliminary outlook for fiscal year 2025.
The elevated estimates for Quest Diagnostics come on the heels of robust third-quarter performances and a strong preliminary outlook for 2025. The company's prospects for earnings remain promising, bolstered by consistent healthcare utilization trends, market share expansions, and a favorable mix.
The lab sector is viewed positively for its prospects in 2025, with the belief that there shouldn't be hesitation in favoring one company on the basis of cost alone. Quest Diagnostics is recognized for having several catalysts that may contribute to hastened growth in 2025, bolstered by a series of eight acquisitions expected to complete in 2024, which should sustain the company's momentum into the following year.
Here are the latest investment ratings and price targets for $Quest Diagnostics (DGX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.